Preclinical News and Research

RSS

FDA approves Nastech vitamin B-12 deficiency nasal spray

Nastech Pharmaceutical Company has announced receipt of an approvable letter from the U.S. Food and Drug Administration (FDA) on Nascobal (Cyanocobalamin, USP) Nasal Spray for the treatment of vitamin B-12 deficiency.

1 Nov 2004

Human Genome Sciences announces agreement with GSK for development of drug to treat diabetes

Human Genome Sciences today announced an agreement with GlaxoSmithKline under which GlaxoSmithKline has acquired exclusive worldwide rights to develop and commercialize Albugon (albumin-glucagon-like peptide-1, GLP-1), a drug currently in late-stage preclinical development by Human Genome Sciences for potential use in the treatment of diabetes.

26 Oct 2004

Ruboxistaurin may reduce vision loss from diabetes-induced eye disease

Eli Lilly and Company's investigational compound ruboxistaurin may reduce vision loss from diabetes-induced eye disease, according to new analyses of previously reported data presented at the 2004 Joint Meeting of the American Academy of Ophthalmology and the European Society of Ophthalmology in New Orleans, La.

26 Oct 2004

Radiotherapy with cetuximab significantly improves disease control and survival in head and neck cancer

Combination treatment using the monoclonal antibody cetuximab, along with high dose radiotherapy in the treatment of patients with loco-regionally advanced squamous cell carcinoma of the head and neck results in significant improvements in both loco-regional control and overall survival, according to Dr Jordi Giralt of Val d'Hebron University Hospital.

26 Oct 2004

The aging American population means that more people are at risk for stroke

A leading stroke researcher says the aging of the American population means that more people are at risk for stroke, and unless new approaches are developed to reduce stroke incidence, it will surpass heart attacks and cancer as the major cause of long-term disability and premature death.

22 Oct 2004

QIMR researchers have received a 5 year grant to develop a vaccine against Group A streptococcus

QIMR researchers have received a 5 year grant from the National Institutes of Health in the USA to develop a vaccine against Group A streptococcus. This extremely prestigious grant makes QIMR one of the most successful recipients of NIH funding in Australia.

18 Oct 2004

MedImmune progresses development of Respiratory Syncytial Virus and Parainfluenza Virus Type-3 vaccines

MedImmune has announced that data from a preclinical study for its lead vaccine candidate to prevent respiratory syncytial virus (RSV) and parainfluenza virus type-3 (PIV-3) has shown a protective immune response against both viruses in animals.

13 Oct 2004

Researchers stimulate the body to repair tissue damaged by peripheral arterial obstructive disease

Duke University Medical Center researchers have shown that they can stimulate the body to produce its own naturally occurring growth factors to promote blood vessel growth into tissue damaged by peripheral arterial obstructive disease (PAOD).

13 Oct 2004

A novel gene therapy strategy may help reduce seizures in adults suffering from epilepsy

Deborah Lin, from the Faculty of Medical and Health Sciences, is investigating the effects of a therapeutic gene transfer in a particular form of epilepsy which affects the brain’s temporal lobe region.

12 Oct 2004

Boosting the blood count in conjunction with radiation therapy doesn't improve survival for head and neck cancer patients

Boosting the blood count – in effect, curing anemia – in conjunction with radiation therapy won't help patients with head and neck cancer fare any better than with radiation alone, says a national study led by Jefferson Medical College researchers.

5 Oct 2004

FDA fast tracks Genaera's drug for the treatment of wet age-related macular degeneration

Genaera Corporation has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to squalamine, an intravenously administered, first in class, small molecule anti-angiogenic drug for the treatment of "wet" age-related macular degeneration (AMD).

4 Oct 2004

Novel compound that resembles vitamin E halves the size of tumors and the ability of cancer to spread

By studying cancer in mice, researchers at The University of Texas at Austin have gained preliminary evidence that a novel compound that resembles vitamin E halves the size of tumors and the ability of cancer to spread to other body sites.

30 Sep 2004

Large-scale screening programme of tonsil tissue is the only way of identifying the true incidence of vCJD infection

A study in this week’s issue of THE LANCET describes how two different types of analysis used in conjunction on samples of tonsil tissue is the ‘gold standard’ method for confirming clinical variant CJD

30 Sep 2004

Scientists embark on a five-year study of the effects of soy isoflavones found in dietary supplements on various body tissues

A multidisciplinary team of scientists at the University of Illinois at Urbana-Champaign is embarking on a comprehensive five-year study of the effects of soy isoflavones found in dietary supplements on various body tissues.

29 Sep 2004

Cancer vaccine based on listeria bacteria shows promise

An experimental cancer vaccine using defanged listeria bacteria is showing great promise in animal studies, successfully treating new cancers that have spread into the lungs of mice.

29 Sep 2004

Phase II trials of the first second-generation antisense cancer drug to be used in patients soon to be underway

Phase II trials of the first second-generation antisense cancer drug to be used in patients are soon to be underway in the wake of a successful Phase I study, which has demonstrated that the new drug blocks its target gene in exactly the way it is designed to do.

28 Sep 2004

Elan and Wyeth receive patents for Alzheimer's disease treatments

Elan Corporation and Wyeth Pharmaceuticals have announced that the United States Patent and Trademark Office recently issued Neuralab Limited, a subsidiary of Elan, seven patents for the companies’ joint research on immunotherapeutic approaches to the prevention and treatment of Alzheimer’s disease.

23 Sep 2004

Preclinical News and Research

FDA approves Nastech vitamin B-12 deficiency nasal spray

Human Genome Sciences announces agreement with GSK for development of drug to treat diabetes

Ruboxistaurin may reduce vision loss from diabetes-induced eye disease

Radiotherapy with cetuximab significantly improves disease control and survival in head and neck cancer

The aging American population means that more people are at risk for stroke

QIMR researchers have received a 5 year grant to develop a vaccine against Group A streptococcus

MedImmune progresses development of Respiratory Syncytial Virus and Parainfluenza Virus Type-3 vaccines

Researchers stimulate the body to repair tissue damaged by peripheral arterial obstructive disease

A novel gene therapy strategy may help reduce seizures in adults suffering from epilepsy

Boosting the blood count in conjunction with radiation therapy doesn't improve survival for head and neck cancer patients

FDA fast tracks Genaera's drug for the treatment of wet age-related macular degeneration

Novel compound that resembles vitamin E halves the size of tumors and the ability of cancer to spread

Large-scale screening programme of tonsil tissue is the only way of identifying the true incidence of vCJD infection

Scientists embark on a five-year study of the effects of soy isoflavones found in dietary supplements on various body tissues

Cancer vaccine based on listeria bacteria shows promise

Phase II trials of the first second-generation antisense cancer drug to be used in patients soon to be underway

Elan and Wyeth receive patents for Alzheimer's disease treatments

Scientists have corrected a flaw in cancer cells that lets them evade the normal cell-death process

Stress response proteins offer a promising target for a novel drug guidance system

Certain cancers might one day be cured without the use of toxic chemotherapy and radiation

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News